(RTTNews) – Akari Therapeutics, Plc (AKTX) on Tuesday announced advances in its COVID-19 pneumonia program with nomacopan in the United States and Brazil.
The company noted that COVID-19 pneumonia is a leading cause of death in PATIENTS with COVID-19 and that, despite innovations in quality of care, it remains difficult to treat.
Clive Richardson, CEO of Akari Therapeutics, said: “We are pleased to report the continued progress of our COVID-19 pneumonia program. In addition to its possible remedy for COVID-19 pneumonia, we believe that the dual supplement of nomacopan and inhibition of Leukotriene has applicability in a variety of other serious pulmonary inflammatory conditions that we are exploring, such as COVID pneumonia, which have proven difficult to treat due to the involvement of multiple inflammatory pathways. “
Data from several clinical studies in patients with COVID-19 pneumonia have shown the key role of the supplement C5a and C5b9, as well as the accumulation of neutrophils in the lungs, resulting in severe inflammation and dramatic relief in the distribution of blood through the pylous bed of the lung and in the end other organs.
The company’s first early test studies have shown that the forty-five mg dose of nomacopan can be used to treat patients with COVID-19 pneumonia without the need for an overdose. Studies have shown an immediate onset of nomacopan action, as well as no reported signs of adverse protection in this fragile group of patients.
The two studies in the United States and Brazil are randomized, double-blind (2:1 in favor of nomacopan treatment) clinical studies involving more than 60 patients, with oxygen standardization and hospital discharge as the number one criterion for trial. will come with the need for intubation and mortality.
Patients will get a subcutaneous dose of nomacopan and a popular treatment or placebo and a popular treatment. Treatment lasts up to 14 days, with follow-up of the exam and final touch after two months.
Akari Therapeutics said it invited him to provide an update on its COVID-19 pneumonia program at the 4th Annual Summit on The Development of Complementary Medicines 2020 on 15 October 2020.